Detalles de la búsqueda
1.
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Eur J Neurol
; 30(7): 1945-1956, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35837793
2.
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
Pharm Stat
; 16(6): 396-413, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28691311
3.
Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function.
Pharm Stat
; 14(6): 479-87, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26353113
4.
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
J Neurol
; 270(5): 2531-2546, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36735057
5.
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Lancet Neurol
; 21(1): 42-52, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34942136
6.
Correction to: Twoyear efficacy and safety of risdiplam in patients with type 2 or nonambulant type 3 spinal muscular atrophy (SMA).
J Neurol
; 270(5): 2547-2549, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37071150
Resultados
1 -
6
de 6
1
Próxima >
>>